TITLE

Recently Approved

PUB. DATE
July 2007
SOURCE
Pharmaceutical Representative;Jul2007, Vol. 37 Issue 7, p14
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the drugs approved in the U.S. as of July 2007. The use of Inspire Pharmaceuticals Inc.'s AzaSite (azithromycin ophthalmic solution) for bacterial conjunctivitis was approved by the Food and Drug Administration (FDA). A marketing authorization was given to Dey L.P. for its Perforomist (formoterol fumarate) inhalation solution. The FDA approved the use of Janssen L.P.'s atypical antipsychotic Invega tablets for the treatment of schizophrenia.
ACCESSION #
25585217

 

Related Articles

  • RESPIRATORY DISORDERS.  // MPR - Pediatricians' Edition;Spring/Summer2014, Vol. 25 Issue 1, p139 

    The article offers information on several drugs for treating respiratory disorders including AstraZeneca PLC's Accolate, GlaxoSmithKline's Advair HFA, and Dey Pharma LP's Accuneb.

  • ALLERGIC DISORDERS: 1B Anaphylaxis.  // MPR - Pharmacist's Edition;Fall2011, Vol. 5 Issue 3, p3 

    The article offers information on various drugs and its proper administration for Anaphylaxis such as Adrenaclick from Shionogi & Co. Ltd. and Epipen from Dey Pharma LP.

  • Sponsors.  // CenterWatch Weekly;2/3/2014, Vol. 18 Issue 5, p3 

    The article offers news briefs related to the pharmaceutical industry including Medigene, Janssen , and BioEnterprise.

  • FDA approves Cyanokit for treating cyanide poisoning.  // Fire Engineering;Feb2007, Vol. 160 Issue 2, p42 

    The article discusses the release of a new drug called Cyanokit, which will be used in treating cyanide poisoning from smoke inhalation. The U.S. Food and Drug Administration has approved the drug, made by EMD Pharmaceuticals and Dey LP, which binds directly to cyanide ions, creating...

  • Decisions Update.  // PharmaWatch: Biotechnology;Jan2006, Vol. 5 Issue 1, p12 

    This article presents an update on decisions taken by pharmaceutical companies. The U.S. Food and Drug Administration (FDA) has approved Halozyme Therapeutics Inc.'s drug Hylenex for use as an adjuvant agent to increase the dispersion and absorption of other injected drugs. Baxter Healthcare...

  • Makers wait for folks to take their medicine.  // Business North Carolina;Feb2004, Vol. 24 Issue 2, p56 

    Deals with the performance of pharmaceutical companies in North Carolina in 2003. Approval received by Trimeris from the U.S. Food and Drug Administration for its AIDS drug Fuzeon; Information on the Diquafosol dry-eye disease drug of Inspire Pharmaceuticals; Move of Quintiles Transnational to...

  • CLINIC ROUNDUP.  // BioWorld Today;7/12/2007, Vol. 18 Issue 134, p7 

    This section offers news briefs on issues related to drug trials. Cell Therapeutics Inc. highlights the results of the interim Phase II/III trial of pixantrone-based combination therapy. Geron Corp. has initiated a Phase I/II trial of GRNVAC1 telomerase cancer vaccine in patients with acute...

  • SECTION 8: EYE DISORDERS.  // Monthly Prescribing Reference;Sep2010, Vol. 26 Issue 9, p136 

    The article presents a drug study on several drugs for eye disorders focusing on ocular infections. It shows drug summary on pharmaceutical products including Azasite from Inspire Pharmaceuticals Inc., Bacitracin Ophthalmic Ointment from Fera Pharmaceuticals LLC, and Besivance from Bausch & Lomb...

  • Inspire Nasal Spray Trial Fails and Program Halted.  // Bioworld Week;4/28/2008, Vol. 16 Issue 17, p4 

    The article reports on Inspire Pharmaceuticals Inc.'s decision to suspend development of its epinastine nasal spray. The decision comes after a Phase III study showed that it did have significant results compared to placebo, based on incidents of runny nose, itchy nose, and sneezing. According...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics